Holen Sie sich die Stockscreener-App
72.07
0.80%
0.54
Schlusskurs vom Vortag:
$71.53
Offen:
$71.3
24-Stunden-Volumen:
242.98K
Relative Volume:
0.29
Marktkapitalisierung:
$7.60B
Einnahmen:
$628.56M
Nettoeinkommen (Verlust:
$141.82M
KGV:
57.20
EPS:
1.26
Netto-Cashflow:
$142.60M
1W Leistung:
-20.17%
1M Leistung:
-1.05%
6M Leistung:
+6.93%
1J Leistung:
+59.17%
1-Tages-Spanne:
$69.43
$72.72
1-Wochen-Bereich:
$69.43
$91.00
52-Wochen-Spanne:
$42.01
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Vergleichen Sie CORT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
72.14 | 7.79B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.81 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.43 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.88 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
794.98 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
322.71 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Corcept Therapeutics (CORT) Seeks EMA Approval for Relacorilant in Cancer Treatment - GuruFocus
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Stock Titan
Corcept Therapeutics Incterminates distribution agreement with Optime CareSEC filing - MarketScreener
Corcept Therapeutics Incorporated $CORT Holdings Trimmed by Aberdeen Group plc - MarketBeat
What momentum indicators show for Corcept Therapeutics Incorporated stockQuarterly Market Summary & Risk Controlled Stock Pick Alerts - newser.com
Is Corcept Therapeutics Incorporated stock positioned well for digital economyEarnings Summary Report & Weekly Market Pulse Updates - newser.com
What moving averages say about Corcept Therapeutics Incorporated2025 Biggest Moves & AI Powered Buy and Sell Recommendations - newser.com
Technical analysis overview for Corcept Therapeutics Incorporated stockPortfolio Growth Summary & High Accuracy Trade Alerts - newser.com
Volume spikes in Corcept Therapeutics Incorporated stock – what they mean2025 Retail Activity & Safe Capital Growth Tips - newser.com
How Corcept Therapeutics Incorporated stock compares to growth peers2025 Year in Review & Stock Portfolio Risk Control - newser.com
Corcept Therapeutics (CORT) Stock Analysis: A Promising 82.87% Upside in the Biotech Sector - DirectorsTalk Interviews
Momentum divergence signals in Corcept Therapeutics Incorporated chart2025 Retail Activity & AI Driven Price Forecasts - newser.com
How sentiment analysis helps forecast Corcept Therapeutics IncorporatedJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Corcept Therapeutics (CORT) Is Down 16.1% After Distribution Shift and Insider Selling—What's Changed - Yahoo Finance
Maryland State Retirement & Pension System Has $2.37 Million Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Insider William Guyer Sells 20,000 Shares - MarketBeat
Corcept Therapeutics (CORT) Sees Significant Drop of 13.3% - GuruFocus
Why Corcept (CORT) Shares Are Falling Today - The Globe and Mail
3 Profitable Stocks That Concern Us - The Globe and Mail
Corcept Therapeutics (CORT) Shares Drop as Optime Care Ends Dist - GuruFocus
Corcept Therapeutics (CORT) Adjusts Korlym Distribution Strategy - GuruFocus
Corcept Therapeutics (CORT) Shares Drop Amid Market Activity - GuruFocus
Analyzing Corcept Therapeutics Incorporated with risk reward ratio chartsQuarterly Market Summary & Community Consensus Trade Alerts - newser.com
Corcept Therapeutics (CORT) Rating Reiterated as 'Buy' by HC Wai - GuruFocus
Corcept Therapeutics' (CORT) "Hold (C)" Rating Reiterated at Weiss Ratings - MarketBeat
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight - The Malaysian Reserve
Corcept Therapeutics Incorporated stock trend outlook and recovery pathWeekly Profit Recap & Daily Volume Surge Signals - newser.com
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 4.9%Here's Why - MarketBeat
Corcept Therapeutics Board Member Resigns, Continues as Consultant - MSN
Pre-ESMO insights: Corcept on platinum-resistant ovarian cancer - pharmaphorum
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Genmab (GMAB) - The Globe and Mail
Corcept's NDA for its hypercortisolism treatment gets FDA nod - MSN
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm - The Globe and Mail
Myasthenia Gravis Pipeline Outlook Report 2025: Novel Therapeutics, Clinical Advancements, and Opportunities - The Globe and Mail
'This isn't a dress rehearsal': Why the coming months could be big for a Peninsula drug company that has survived decades - The Business Journals
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135 - 富途牛牛
What Fibonacci levels say about Corcept Therapeutics Incorporated reboundWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com
Will Corcept Therapeutics Incorporated bounce back from current supportQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
Is a relief rally coming for Corcept Therapeutics Incorporated holdersJuly 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
QRG Capital Management Inc. Acquires 13,829 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Why Corcept Therapeutics Incorporated stock is seen as undervalued2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com
Visual analytics tools that track Corcept Therapeutics Incorporated performance2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
Is Corcept Therapeutics Incorporated (HTD) stock undervalued by metricsJuly 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com
Earnings Tell The Story For Corcept Therapeutics Incorporated (NASDAQ:CORT) As Its Stock Soars 27% - 富途牛牛
JSF Financial LLC Makes New Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (CORT): Evaluating Valuation After New Curant Health Partnership and Pipeline Progress - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 5,000 Shares - MarketBeat
Low-Volatility Stocks Underperforming: RSI, ADT, CORT AnalysisNews and Statistics - IndexBox
Here’s What Makes Corcept Therapeutics (CORT) an Attractive Investment? - Yahoo Finance
Synergy Asset Management LLC Raises Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.84%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):